FIELD: chemistry.
SUBSTANCE: invention relates to a new compound of formula (I), or its tautomer, or a pharmaceutically acceptable salt. Compounds possess the properties of phosphodiesterase inhibitors (PDE2) and tumor necrosis factor α (TNFα). Activity of the compounds with respect to PDE2 is less than 50 mcM and in some cases less than 10 mcM, and in relation to α (TNFα) it can reach 60–80 % and more. In the compound of formula (I) 
(I), fragment 
can be replaced with 
A ring is selected from 
, 
G is selected from 
L is 
CH2, 
or L is 
R1 is bonded with G to form a spiro ring selected from 
or 
EFFECT: compounds can be used for treating inflammatory diseases, such as arthritis, vasculitis, inflammatory intestinal diseases, as well as to participate, for example, in reducing the degree of cerebral dysfunction.
4 cl, 2 tbl, 117 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HYDROXYPURINE COMPOUNDS AND WAYS OF THEIR USE | 2015 |
|
RU2673458C1 |
| QUINOLINE DERIVATIVES AS SMO INHIBITORS | 2015 |
|
RU2695815C2 |
| REGULATORS-DERIVATIVES OF STEROIDS, METHODS OF THEIR OBTAINING AND THEIR USE | 2019 |
|
RU2797408C2 |
| REGULATORS OF DERIVATIVES OF STEROIDS, METHODS OF THEIR OBTAINING AND USE | 2019 |
|
RU2803499C1 |
| BICYCLIC KETONES AND METHODS OF THEIR USE | 2018 |
|
RU2797922C2 |
| S1P1 AGONIST AND ITS APPLICATION | 2017 |
|
RU2754845C2 |
| NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVES AND USE THEREOF IN MEDICINAL PREPARATIONS | 2014 |
|
RU2694254C1 |
| SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK, THEIR PREPARATION AND USE IN TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASES | 2014 |
|
RU2677884C2 |
| PHENOXYPYRIDINYLAMIDE DERIVATIVES, AND THEIR USE IN TREATMENT OF PDE4-MEDIATED DISEASE STATES | 2009 |
|
RU2509077C2 |
| HETEROCYCLIC COMPOUNDS FOR TYROSINE KINASE 2 ACTIVITY MEDIATION | 2020 |
|
RU2826012C2 |
